⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Taisho Pharmaceuticals (Philippines), Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Taisho Pharmaceuticals (Philippines), Inc.
↗Taguig, Philippines
Taisho Pharmaceuticals (Philippines), Inc. is a subsidiary of the Japanese multinational Taisho Pharmaceutical Co., Ltd. The company focuses on the manufacture, import, distribution, and management of pharmaceuticals, OTC drugs, and health-related products, including energy drinks and supplements.
Operating in the Philippines since 1992, the company plays a significant role in the local healthcare market by providing a portfolio that includes proprietary medicines (e.g., Tempra, Bonamine), prescription medications (e.g., Flanax), and consumer health products (e.g., Lipovitan, Vivalyte). The company is committed to improving healthcare accessibility and affordability through strategic partnerships, such as its recent alliance with AC Health Pharma.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Pharmaceutical Preparation Manufacturing
SIZE & FINANCIALS
Employees:51-200
Founded:1992
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Taisho Pharmaceutical Co., Ltd. (Japan)
Key Partnerships:AC Health Pharma (Strategic partnership to expand access to healthcare products in the Philippines)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Jiang Peng - President and General Manager
Keisuke Yoshikawa - Commercial Excellence Head
LINKS
Website:taisho.com.ph
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Taisho Pharmaceuticals (Philippines), Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.